MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: Tricuspid valve replacement: bioprostheses are preferable.
Author: Dalrymple-Hay MJ, Leung Y, Ohri SK, Haw MP, Ross JK, Livesey SA, Monro JL.
Journal: J Heart Valve Dis; 1999 Nov; 8(6):644-8. PubMed ID: 10616242.
Abstract:
BACKGROUND AND AIM OF THE STUDY: Tricuspid valve replacement (TVR) is rarely undertaken, most surgeons preferring to use conservative tricuspid valve procedures. Thus, limited data are available in patients following TVR. The purpose of this study was to analyze the early and late results in 87 patients (52 tissue valves, 35 mechanical prostheses) who underwent TVR between January 1973 and September 1996. METHODS: The patient group comprised 74 (85%) females and 13 (15%) males; mean (+/- SD) age was 59.4 +/- 12.8 years; range: 15 to 81 years). Forty-four patients (51%) had undergone at least one previous cardiac operation. There were 19 (23%) isolated TVRs, 43 (49%) triple valve replacements, and 25 (29%) double valve replacements. Total cumulative follow up was 707 patient-years (pt-yr) (tissue valves 393 pt-yr, mechanical valves 314 pt-yr); mean follow up was 8.1 years (range: 0 to 23.6 years). RESULTS: The early (30-day) mortality rate was 10.3% (n = 9; tissue 7, mechanical 2, p = 0.28). Logistic regression identified prolonged cardiopulmonary bypass time (p <0.03) and advanced NYHA functional class (p <0.007) as risk factors for operative death. No risk factors were significant on multiple logistic regression analysis. Mean (+/- SEM) survival rate was 68 +/-5.3% (n = 50) at 5 years, 52 +/- 5.9% (n = 36) at 10 years, 35 +/- 6% (n = 20) at 15 years, and 16 +/- 5.3% (n = 7) at 20 years. Freedom from tricuspid valve reoperation at 5, 10 and 15 years was 93 +/- 3.3% (n = 46), 83 +/- 5.8% (n = 33) and 71 +/- 2.8% (n = 17) respectively. Eleven patients required tricuspid valve reoperation: six mechanical valves (five for prosthetic valve thrombosis and one for mechanical failure secondary to pannus ingrowth), and five tissue valves (two for prosthetic valve endocarditis and three for prosthetic valve degeneration). Freedom from reoperation at 5, 10 and 15 years for tissue prostheses was 97 +/- 2.5%, 89 +/- 6.3% and it was 70 +/- 12%, and 86 +/- 7.4%, 74 +/- 9.9% and 68 +/-11% for mechanical prostheses. The mechanical prostheses required reoperation earlier after the initial surgery. CONCLUSIONS: We recommend the use of a bioprosthesis in the tricuspid position because of its initial durability and low reoperation rate.

[Abstract] [Full Text] [Related] [New Search]